Biography:
Phil Pagni holds a PhD in Immunology from Aix-Marseille University obtained at the Center of Immunology of Marseille-Luminy. He pursued his postdoctoral training at the La Jolla Institute for Immunology (LJI) in Prof. Matthias von Herrath’s lab, evaluating immune-mediated combination therapies to prevent or reverse the course of type 1 diabetes in mouse models.
At Novo Nordisk since 2013, Phil is a scientist experienced in immunology and autoimmunity including type 1 diabetes. As Head of the Immunobiology department in Lexington, Phil’s mission is to provide safe, immune-mediated targets across various cardiometabolic and rare diseases within Novo Nordisk’s pipeline.
Title : Impact of liraglutide treatment on gene expression in peripheral T-Cell populations from adults with recently diagnosed Type 1 diabetes